Literature DB >> 6973016

Prevalence of Pneumocystis carinii pneumonitis in severe combined immunodeficiency.

R J Leggiadro, J A Winkelstein, W T Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6973016     DOI： 10.1016/s0022-3476(81)80967-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  5 in total

Review 1.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

2.  Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; M Sarić; R W Grady
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

3.  Alterations in cysteine proteinase content of rat lung associated with development of Pneumocystis carinii infection.

Authors:  D J Hayes; C R Stubberfield; J D McBride; D L Wilson
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

4.  Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia.

Authors:  A B Clarkson; D E Williams; C Rosenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

5.  Pathogens in children with severe combined immune deficiency disease or AIDS.

Authors:  D Lauzon; G Delage; P Brochu; J Michaud; G Jasmin; J H Joncas; N Lapointe
Journal:  CMAJ       Date:  1986-07-01       Impact factor: 8.262
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.